Randomized, double blind, placebo-controlled trial of fish-oil-based lipid emulsion infusion for treatment of critically ill patients with severe sepsis

Boon Siang Khor, Shiumn Jen Liaw, Hsin Chin Shih, Liang Shun Wang

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

OBJECTIVE: The present study aimed to determine the clinical benefits to critically ill patients with severe sepsis of receiving parenteral fish-oil-based lipid emulsion as adjuvant treatment. METHODS: This was a prospective, randomized, double-blind, placebo-controlled clinical trial of 28 patients with severe sepsis in the intensive care unit of a primary and referral teaching hospital. RESULTS: Fourteen patients were randomly assigned to the study group and a similar number were placed in the control group. The study group showed a significant score reduction for Acute Physiology and Chronic Health Evaluation (APACHE) II on day 3 (p = 0.004), day 5 (p = 0.032) and day 7 (p = 0.03), together with APACHE III (p = 0.028) and Simplified Acute Physiology Score II (p = 0.019) on day 7. The serum procalcitonin level was significantly decreased in the study group on day 3 (p = 0.018), day 5 (p = 0.011) and day 7 (p = 0.028). However, the serum tumour necrosis factor-á level, length of intensive care unit and hospital stay showed no significant difference when the groups were compared. CONCLUSION: Adjuvant treatment with fish-oil-based lipid emulsion of 10% Omegaven for critically ill patients with severe sepsis is probably safe and helpful for rapid reduction of clinical severity of the disease.

Original languageEnglish
Pages (from-to)1-10
Number of pages10
JournalAsian Journal of Surgery
Volume34
Issue number1
DOIs
Publication statusPublished - Jan 2011

Fingerprint

Fish Oils
Emulsions
Critical Illness
Sepsis
Placebos
Lipids
APACHE
Intensive Care Units
Controlled Clinical Trials
Calcitonin
Therapeutics
Serum
Teaching Hospitals
Length of Stay
Referral and Consultation
Tumor Necrosis Factor-alpha
Control Groups

Keywords

  • clinical assessment
  • fish oil-based lipid emulsion
  • severe sepsis

ASJC Scopus subject areas

  • Surgery

Cite this

Randomized, double blind, placebo-controlled trial of fish-oil-based lipid emulsion infusion for treatment of critically ill patients with severe sepsis. / Khor, Boon Siang; Liaw, Shiumn Jen; Shih, Hsin Chin; Wang, Liang Shun.

In: Asian Journal of Surgery, Vol. 34, No. 1, 01.2011, p. 1-10.

Research output: Contribution to journalArticle

@article{53d8fec2734647d0b723922faa50f22e,
title = "Randomized, double blind, placebo-controlled trial of fish-oil-based lipid emulsion infusion for treatment of critically ill patients with severe sepsis",
abstract = "OBJECTIVE: The present study aimed to determine the clinical benefits to critically ill patients with severe sepsis of receiving parenteral fish-oil-based lipid emulsion as adjuvant treatment. METHODS: This was a prospective, randomized, double-blind, placebo-controlled clinical trial of 28 patients with severe sepsis in the intensive care unit of a primary and referral teaching hospital. RESULTS: Fourteen patients were randomly assigned to the study group and a similar number were placed in the control group. The study group showed a significant score reduction for Acute Physiology and Chronic Health Evaluation (APACHE) II on day 3 (p = 0.004), day 5 (p = 0.032) and day 7 (p = 0.03), together with APACHE III (p = 0.028) and Simplified Acute Physiology Score II (p = 0.019) on day 7. The serum procalcitonin level was significantly decreased in the study group on day 3 (p = 0.018), day 5 (p = 0.011) and day 7 (p = 0.028). However, the serum tumour necrosis factor-{\'a} level, length of intensive care unit and hospital stay showed no significant difference when the groups were compared. CONCLUSION: Adjuvant treatment with fish-oil-based lipid emulsion of 10{\%} Omegaven for critically ill patients with severe sepsis is probably safe and helpful for rapid reduction of clinical severity of the disease.",
keywords = "clinical assessment, fish oil-based lipid emulsion, severe sepsis",
author = "Khor, {Boon Siang} and Liaw, {Shiumn Jen} and Shih, {Hsin Chin} and Wang, {Liang Shun}",
year = "2011",
month = "1",
doi = "10.1016/S1015-9584(11)60011-0",
language = "English",
volume = "34",
pages = "1--10",
journal = "Asian Journal of Surgery",
issn = "1015-9584",
publisher = "Elsevier Taiwan LLC",
number = "1",

}

TY - JOUR

T1 - Randomized, double blind, placebo-controlled trial of fish-oil-based lipid emulsion infusion for treatment of critically ill patients with severe sepsis

AU - Khor, Boon Siang

AU - Liaw, Shiumn Jen

AU - Shih, Hsin Chin

AU - Wang, Liang Shun

PY - 2011/1

Y1 - 2011/1

N2 - OBJECTIVE: The present study aimed to determine the clinical benefits to critically ill patients with severe sepsis of receiving parenteral fish-oil-based lipid emulsion as adjuvant treatment. METHODS: This was a prospective, randomized, double-blind, placebo-controlled clinical trial of 28 patients with severe sepsis in the intensive care unit of a primary and referral teaching hospital. RESULTS: Fourteen patients were randomly assigned to the study group and a similar number were placed in the control group. The study group showed a significant score reduction for Acute Physiology and Chronic Health Evaluation (APACHE) II on day 3 (p = 0.004), day 5 (p = 0.032) and day 7 (p = 0.03), together with APACHE III (p = 0.028) and Simplified Acute Physiology Score II (p = 0.019) on day 7. The serum procalcitonin level was significantly decreased in the study group on day 3 (p = 0.018), day 5 (p = 0.011) and day 7 (p = 0.028). However, the serum tumour necrosis factor-á level, length of intensive care unit and hospital stay showed no significant difference when the groups were compared. CONCLUSION: Adjuvant treatment with fish-oil-based lipid emulsion of 10% Omegaven for critically ill patients with severe sepsis is probably safe and helpful for rapid reduction of clinical severity of the disease.

AB - OBJECTIVE: The present study aimed to determine the clinical benefits to critically ill patients with severe sepsis of receiving parenteral fish-oil-based lipid emulsion as adjuvant treatment. METHODS: This was a prospective, randomized, double-blind, placebo-controlled clinical trial of 28 patients with severe sepsis in the intensive care unit of a primary and referral teaching hospital. RESULTS: Fourteen patients were randomly assigned to the study group and a similar number were placed in the control group. The study group showed a significant score reduction for Acute Physiology and Chronic Health Evaluation (APACHE) II on day 3 (p = 0.004), day 5 (p = 0.032) and day 7 (p = 0.03), together with APACHE III (p = 0.028) and Simplified Acute Physiology Score II (p = 0.019) on day 7. The serum procalcitonin level was significantly decreased in the study group on day 3 (p = 0.018), day 5 (p = 0.011) and day 7 (p = 0.028). However, the serum tumour necrosis factor-á level, length of intensive care unit and hospital stay showed no significant difference when the groups were compared. CONCLUSION: Adjuvant treatment with fish-oil-based lipid emulsion of 10% Omegaven for critically ill patients with severe sepsis is probably safe and helpful for rapid reduction of clinical severity of the disease.

KW - clinical assessment

KW - fish oil-based lipid emulsion

KW - severe sepsis

UR - http://www.scopus.com/inward/record.url?scp=79955394406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955394406&partnerID=8YFLogxK

U2 - 10.1016/S1015-9584(11)60011-0

DO - 10.1016/S1015-9584(11)60011-0

M3 - Article

C2 - 21515206

AN - SCOPUS:79955394406

VL - 34

SP - 1

EP - 10

JO - Asian Journal of Surgery

JF - Asian Journal of Surgery

SN - 1015-9584

IS - 1

ER -